UG
UG2.F AngioDynamics Inc
- Market cap
- EUR 450M
- P/E
- -
- P/B
- 3.18x
- ROE
- -17.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is UG2.F undervalued?
Graham numberThe Graham number of AngioDynamics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AngioDynamics Inc fundamental analysis
No fundamental analysis for AngioDynamics Inc yet.
AngioDynamics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVa…
Full company profileAngioDynamics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AngioDynamics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 350M | 344M | 271M | 264M | 291M | 316M | 339M | 304M | 292M | 320M | 324M |
| Gross Profit | 176M | 177M | 156M | 150M | 157M | 166M | 174M | 155M | 158M | 175M | 192M |
| Operating Income | 25.2M | 26.2M | -1.05M | -14.0M | -15.0M | -18.2M | -18.7M | -33.8M | -24.1M | -22.3M | -20.5M |
| EBITDA | 37.5M | 33.7M | 16.3M | -143M | -9.28M | 88.0K | -20.9M | -6.13M | 1.74M | 626K | -6.84M |
| Net Income | 5.01M | 16.3M | -11.1M | -167M | -31.5M | -26.5M | -52.4M | -184M | -34.0M | -36.7M | -28.4M |
| EPS | 0.14 | 0.44 | -0.30 | -4.38 | -0.83 | -0.68 | -1.32 | -4.56 | -0.83 | -0.88 | -0.67 |
| Balance Sheet | |||||||||||
| Total Assets | 708M | 705M | 836M | 594M | 561M | 553M | 533M | 318M | 280M | 267M | 242M |
| Total Liabilities | 193M | 163M | 222M | 139M | 122M | 128M | 154M | 112M | 97.2M | 96.3M | 78.0M |
| Shareholders' Equity | 515M | 543M | 615M | 455M | 439M | 424M | 378M | 206M | 183M | 171M | 164M |
| Cash & Short-term Investments | 47.5M | 74.1M | 228M | 54.4M | 48.2M | 28.8M | 44.6M | 76.1M | 55.9M | 53.9M | 34.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.7M | 41.3M | 37.4M | -14.6M | 24.1M | -7.19M | 78.0K | -28.2M | -10.1M | 3.09M | -61.3M |
| Capital Expenditure | 3.00M | 2.39M | 3.12M | 7.24M | 5.19M | 4.30M | 3.81M | 5.77M | 4.46M | 2.58M | 1.52M |
| Free Cash Flow | 52.7M | 37.6M | 34.3M | -22.1M | 10.4M | -11.5M | -4.27M | -33.9M | -14.6M | 508K | -62.8M |
| Ratios | |||||||||||
| ROE | 1.0% | 3.0% | -1.8% | -36.7% | -7.2% | -6.3% | -13.9% | -89.7% | -18.6% | -21.5% | -17.3% |
| ROA | 0.7% | 2.3% | -1.3% | -28.1% | -5.6% | -4.8% | -9.8% | -58.0% | -12.1% | -13.8% | -11.7% |
| Net Profit Margin | 1.4% | 4.7% | -4.1% | -63.1% | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% | -11.5% | -8.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AngioDynamics Inc dividends
AngioDynamics Inc has not paid dividends in the last 9 fiscal years.
Who owns AngioDynamics Inc
- Insiders 13.27%
- Institutions 86.73%
- Public & others 0.00%
- Shares outstanding 42.1M
- Free float 32.8M
AngioDynamics Inc company profile
- Company name
- AngioDynamics Inc
- Ticker
- UG2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 632
- Fiscal year end
- May
- Address
- 14 Plaza Drive, Latham, NY, United States, 12110
- Phone
- 518 795 1400
- Website
- angiodynamics.com
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
AngioDynamics Inc management
10- Mr. Stephen A. TrowbridgeExecutive VP & CFO · born 1974
- Mr. Lawrence T. WeissSenior VP, Chief Legal Officer & Corporate Secretary · born 1970
- Mr. Warren G. NighanSenior Vice President of Regulatory Affairs, Quality & Global Supply Chain · born 1969
- Ms. Laura PiccininiSenior VP and GM of Cardiovascular & International · born 1969
- Mr. Eric HonrothPresident, CEO & Director · born 1971
- Mr. Saleem M. CheeksVice President of Communications
- Mr. Benjamin H. DavisSenior Vice President of Business Development & Strategy · born 1964
- Ms. Marna I. Bronfen-MooreSenior Vice President of Human Resources · born 1967
- Mr. Chad T. CampbellSenior VP and GM of Oncology & Interventional Devices · born 1971
- Ms. Kim L. SeaburySenior Vice President of Information Technology · born 1967